Search our Database of Scientific Publications and Authors

I’m looking for a

    1549 results match your criteria Hidradenitis Suppurativa

    1 OF 31

    Should Hidradenitis Suppurativa Be Included in Dermatoses Showing Koebnerization? Is It Friction or Fiction?
    Dermatology 2017 May 16. Epub 2017 May 16.
    Background: The etiology of hidradenitis suppurativa (HS) involves genetic and environmental factors. Well-established associated systemic factors are obesity, smoking, inflammation, and bacteria. Whether localized environmental factors such as friction and pressure may also play a causative role is still unclear. Read More

    A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
    Nutrients 2017 May 15;9(5). Epub 2017 May 15.
    Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark.
    Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Read More

    Hidradenitis Suppurativa Is Associated with Familial Mediterranean Fever -A Population-Based Study.
    J Invest Dermatol 2017 May 9. Epub 2017 May 9.
    Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Division of Community Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

    Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States.
    JAMA Dermatol 2017 May 10. Epub 2017 May 10.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, New York.
    Importance: The true prevalence of hidradenitis suppurativa (HS) is unknown.

    Objective: To establish standardized overall and group-specific prevalence estimates for HS in the United States.

    Design, Setting, And Participants: This retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. Read More

    Hidradenitis Suppurativa, Intimate Partner Violence, and Sexual Assault.
    J Cutan Med Surg 2017 May 1:1203475417708167. Epub 2017 May 1.
    1 Department of Psychology, University of Windsor, Windsor, Ontario, Canada.
    Background: Sexual assault and intimate partner violence have never been examined in individuals with hidradenitis suppurativa. The research is important, because prior studies show higher incidences of intimate partner violence and sexual assault in individuals with disabilities, and hidradenitis suppurativa meets criteria for a disability.

    Objectives: The objective of the study is to examine whether individuals with hidradenitis suppurativa are at significantly higher risk of intimate partner violence and sexual assault compared with individuals who have acne, a recognised disability. Read More

    Biologics in patients with skin diseases.
    J Allergy Clin Immunol 2017 May;139(5):1423-1430
    Sunnybrook Health Sciences Centre and University of Toronto, Department of Medicine, Division of Dermatology, Toronto, Ontario, Canada. Electronic address:
    Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris. Read More

    [Diagnosis and treatment of hidradenitis suppurativa].
    Ugeskr Laeger 2017 May;179(18)
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined by recurrent nodules, tunnels and scarring involving the intertriginous regions. Although patients with HS present a distinct symptomatology with a subsequent impairment of quality of life, an overall diagnostic time of seven years has been reported. A better and broader understanding of this disease may potentially reduce the diagnostic delay. Read More

    Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment.
    Clin Cosmet Investig Dermatol 2017 19;10:105-115. Epub 2017 Apr 19.
    Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. Read More

    Non-surgical treatments for hidradenitis suppurativa: A systematic review.
    Ann Chir Plast Esthet 2017 Apr 27. Epub 2017 Apr 27.
    Department of plastic, reconstructive and aesthetic surgery, Rangueil hospital, 1, avenue Jean-Poulhès, 31059 Toulouse, France. Electronic address:
    Introduction: The management of hidradenitis suppurativa is multidisciplinary, involving general measures, medical treatment and surgery. Non-surgical treatments, often first-line procedures, mainly concern forms of low-to-moderate severity or, conversely, very severe forms in non-operable patients or those refusing surgery. While many treatments have been attempted, few randomized controlled trials have been conducted, so the choice of treatments is most often based on the personal experience of the clinicians. Read More

    Validation of a Case-Finding Algorithm for Hidradenitis Suppurativa Using Administrative Coding from a Clinical Database.
    Dermatology 2017 Apr 28. Epub 2017 Apr 28.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.
    Background: Requisite to the application of clinical databases for observational research in hidradenitis suppurativa (HS) is the identification of an accurate case cohort.

    Objective: To assess the validity of utilizing administrative codes to establish the HS cohort from a large clinical database.

    Methods: In this retrospective study using chart review as the reference standard, we calculated several estimates of the diagnostic accuracy of at least 1 ICD-9 code for HS. Read More

    Paradoxical psoriasiform reactions to anti-TNFα drugs in hidradenitis suppurativa.
    Br J Dermatol 2017 Apr 26. Epub 2017 Apr 26.
    Dermatology Department, University Hospital of Bordeaux, Bordeaux, France.
    Paradoxical psoriasiform reactions to anti-tumor necrosis factor α (TNFα) agents occur with an incidence of 0.3 to 5.6% in patients with inflammatory bowel diseases and rheumatic diseases(1) . Read More

    Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study.
    Am J Clin Dermatol 2017 Apr 20. Epub 2017 Apr 20.
    Department of Dermatology, Erasmus University Medical Center, Burgemeester s' Jacobplein 51, 3015 CA, Rotterdam, The Netherlands.
    Background: Pruritus is still a forgotten aspect of hidradenitis suppurativa (HS) and, to date, has never been adequately studied.

    Objective: The aim of this study was to determine the prevalence, and explore the characteristics, of pruritus in a well-defined cohort of HS patients.

    Setting: An academic hospital-based cross-sectional study in The Netherlands. Read More

    Hidradenitis Suppurativa Complicating Epithelial Malignancy in Immunocompromised Patient.
    J Assoc Physicians India 2016 Dec;64(12):90-92
    Associate Professor in Medicine.
    Hidradenitis suppurativa complicating epithelial malignancy in people living with HIV is very rare. Hidradenitis suppurativa is very rare seen in only 1% of general population and 4% of young adults. We report a case of Hidradenitis suppurativa complicating an epithelial malignancy in are immunocompromised (HIV reactive) patient. Read More

    Rare "Inverted" Verrucous Carcinoma (Carcinoma Cuniculatum) of the Sacrogluteal Region.
    Int J Surg Pathol 2017 Feb 1:1066896917696753. Epub 2017 Feb 1.
    1 Royal Hobart Hospital, Hobart, Tasmania, Australia.
    A 49-year-old woman with a past history of several infundibular cysts in the head and neck region presented with a 6-month history of a nonhealing perianal abscess on a background of 13 years of chronic sacral-buttock abscesses and discharging sinuses as part of hidradenitis suppurativa. After 2 surgical procedures and inadequate healing, a wide local excision was performed. The surgical specimen revealed an extensive, infiltrating, cystic and deeply penetrating, dermal and subcutaneous neoplasm with multiple fistulous tracts extending to the skin surface. Read More

    The microbiological landscape of anaerobic infections in Hidradenitis Suppurativa: a prospective metagenomic study.
    Clin Infect Dis 2017 Apr 1. Epub 2017 Apr 1.
    Paris Descartes University, Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006, Paris, France.
    Background.: Hidradenitis suppurativa (HS) is a frequent and severe disease of the skin, characterized by recurrent or chronic skinfolds suppurative lesions with a high impact on quality of life. Although considered inflammatory, antimicrobial treatments can improve or lead to clinical remission of HS, suggesting triggering microbial factors. Read More

    The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients.
    J Am Acad Dermatol 2017 Apr 1. Epub 2017 Apr 1.
    Department of Dermatology and Venerology, Rudolfstiftung Hospital, Vienna, Austria; School of Medicine, Sigmund Freud University, Vienna, Austria.
    Background: Effective medical treatment for patients with severe hidradenitis suppurativa (HS) is limited.

    Objectives: We sought to measure the impact of wide local excision on quality of life in HS Hurley grade III patients and to examine the rate of postoperative complications, disease recurrences, and satisfaction with the cosmetic results.

    Methods: Seventy-four patients were enrolled. Read More

    Medical Infrared Thermography assistance in the surgical treatment of axillary Hidradenitis Suppurativa: A case report.
    Int J Surg Case Rep 2017 16;34:56-59. Epub 2017 Mar 16.
    GRESPI, EA 4694, Research Group in Engineering Sciences, University of Reims, Reims, France. Electronic address:
    Background: The purpose of this case report is to highlight for the first time the way Medical Infrared Thermography can be a helpful tool to assist the surgeon in the surgical treatment of Hidradenitis Suppurativa inflammatory disease.

    Methods: A 36-year-old man with a 7-year history of Hidradenitis Suppurativa presented inflammatory nodules in the left axilla area corresponding to Hurley stage II. Choice is made to surgically treat this patient using a wide excision protocol combined with a postoperative second intention healing. Read More

    Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review.
    JAMA Dermatol 2017 May;153(5):458-459
    Department of Dermatology & Academic Wound Healing, Institute of Infection & Immunity, Cardiff University, Wales.
    Clinical Question: Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults?

    Bottom Line: There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, -3.7 to -2. Read More

    Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
    Acta Dermatovenerol Alp Pannonica Adriat 2017 Mar;26(1):21-23
    Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
    A sporadic association between hidradenitis suppurativa and other diseases is reported in the literature, but few authors have described the association with Crohn's disease. Adalimumab is a fully human monoclonal antibody targeted at tumor necrosis factor alpha approved for the treatment of Crohn's disease and, recently, for active moderate to severe hidradenitis suppurativa in adult patients that do not respond adequately to systemic conventional treatment. We report an unusual case of a paradoxical effect of adalimumab in the onset of hidradenitis suppurativa in a 40-year-old woman during the treatment of Crohn's disease. Read More

    Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
    Int J Dermatol 2017 Mar 27. Epub 2017 Mar 27.
    Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
    Autoinflammatory syndromes associated with hidradenitis suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. Read More

    Surgical Management of Hidradenitis Suppurativa: A 14-Year Retrospective Review of 98 Consecutive Patients.
    J Burn Care Res 2017 Mar 15. Epub 2017 Mar 15.
    From the *Department of Surgery, University of Iowa; †Department of Surgery, University of Arkansas and Arkansas Children's Hospital, Little Rock; and ‡Department of Nursing, University of Iowa.
    Hidradenitis suppurativa (HS) is a debilitating suppurative disease of the apocrine/follicular glands. Medical treatment has some efficacy in early-stage disease but is costly and requires frequent physician visits. Advanced disease usually requires surgical intervention. Read More

    Hidradenitis suppurativa gains increasing interest on World Wide Web: a source for patient information?
    Int J Dermatol 2017 Mar 21. Epub 2017 Mar 21.
    Department of Urology, University Hospital Mainz, Mainz, Germany.
    Background: Gathering health information from Internet websites is increasingly utilized by patients. No data exist about hidradenitis suppurativa (HS)-related online health information. Thus, we aimed to study the quality, popularity, readability, and timeliness of the most frequented websites on HS. Read More

    Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.
    Br J Dermatol 2017 Mar 16. Epub 2017 Mar 16.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies could demonstrate that the pro-inflammatory cytokine Interleukin-32 (IL-32) is implicated in the pathogenesis of other inflammatory diseases. Read More

    Steatocystoma multiplex suppurativa: case report of a rare condition.
    An Bras Dermatol 2016 Sep-Oct;91(5 suppl 1):51-53
    Universidade do Estado do Rio de Janeiro (UERJ) - Rio de Janeiro (RJ), Brazil.
    Steatocystoma multiplex is a rare genetic disorder characterized by the presence of hamartomatous malformations at the junction of the pilosebaceous duct. It consists of encapsulated cystic lesions in the dermis, with adjacent sebaceous gland. When associated with inflammation, resembling hidradenitis, it is called steatocystoma multiplex suppurativa, a condition rarely reported. Read More

    The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update.
    J Drugs Dermatol 2017 Feb;16(2):119-124

    The International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, industry partners, payers, and regulatory agencies, was established to develop unified and validated patient-centered outcome measures in dermatology in response to increasing demand to quantify effectiveness of treatments and performance outcomes among providers. IDEOM has chosen to start with psoriasis outcome measures, and then apply its methodology to other dermatologic diseases. In this paper, we review the background and progress to date of IDEOM, including an update of IDEOM activities as of our 2016 meeting in Washington DC, USA. Read More

    Generalized Comedones, Acne, and Hidradenitis Suppurativa in a Patient with an FGFR2 Missense Mutation.
    Front Med (Lausanne) 2017 28;4:16. Epub 2017 Feb 28.
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; King's College, St John's Institute of Dermatology, London, UK.
    Mutations in the fibroblast growth factor-receptor gene 2 (FGFR2) gene have been implicated in numerous diseases, including nevus comedonicus (NC) and naevoid acne that have somatic missense mutations in FGFR2 in the affected tissue. A patient presented in our department with unusual, innumerable large comedones throughout his back reminiscient of NC, as well as multifocal hidradenitis suppurativa and acne. Topical and systemic treatments were unsuccessful. Read More

    Anoperineal disease in Hidradenitis Suppurativa : MR imaging distinction from perianal Crohn's disease.
    Eur Radiol 2017 Mar 13. Epub 2017 Mar 13.
    Department of Radiology, Hôpital Maison Blanche, Avenue du Général Koenig, 51092, Reims Cedex, France.
    Objective: To determine whether Hidradenitis suppurativa (HS)-related anoperineal disease can be distinguished from Crohn's disease (CD) using MRI.

    Methods: Pelvic MRI of 23 HS and 46 CD patients with anoperineal disease between 2007 and 2014 were independently analysed by two radiologists. For diagnosis of HS, sensitivity, specificity and positive likelihood ratios (LRs) of inflammatory features and of their anatomical distribution were calculated and compared to those of CD. Read More

    Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis.
    J Am Acad Dermatol 2017 Mar 9. Epub 2017 Mar 9.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, New York.
    Background: The true incidence of hidradenitis suppurativa (HS) is unknown.

    Objective: To determine standardized incidence estimates for HS in the United States.

    Methods: We used a retrospective cohort analysis, including incident HS cases identified using electronic health records data for a demographically heterogeneous population-based sample of >48 million unique patients across all 4 census regions. Read More

    A Systematic Review and Critical Evaluation of Reported Pathogenic Sequence Variants in Hidradenitis Suppurativa.
    Br J Dermatol 2017 Mar 9. Epub 2017 Mar 9.
    Department of Dermatology, Liverpool Hospital.
    Introduction: Hidradenitis Suppurativa (HS) is a severe chronic inflammatory disorder characterised by recurrent painful deep seated nodules with a predilection to the apocrine bearing areas of skin. A minority of cases of HS are due to mutations in the gamma secretase complex. Contention exists surrounding the pathogenicity of sequence variants and their effects upon notch signalling. Read More

    Squamous cell carcinoma arising in long-standing hidradenitis suppurativa: An overlooked facet of the immunocompromised district.
    Clin Dermatol 2017 Mar - Apr;35(2):225-227. Epub 2016 Oct 27.
    Section of Dermatology, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
    The list of comorbidities and complications associated with hidradenitis suppurativa is extensive. Among the complications of hidradenitis suppurativa, squamous cell carcinoma is considered the most severe. After a meticulous literature research starting from the 1950s, we were able to identify over 90 cases of patients with hidradenitis suppurativa developing squamous cell carcinoma. Read More

    1 OF 31